The national Tekturna pharmaceutical law firm of Nadrich & Cohen are reviewing cases involving the blood pressure drug Tekturna and:
- Tekturna HCT.
These are blood pressure drugs manufactured by Novartis and given to patients for high blood pressure. Sadly, the drug can cause serious kidney complications including kidney failure. We are investigating kidney failure cases throughout the country. Tekturna is a hypertension drug known as a Renin Inhibitor. It is believed to be able to narrow the blood vessels in order to regulate blood pressure. Sadly, it can also cause liver failure and other serious kidney complications. One early study of patients was stopped halfway because of the significant risks of kidney damage, renal complications, non-fatal strokes, hypotension and hyperkalemia.
In December 2011 Novartis publicly stated that Tekturna should not be given to patients who are taking an ACE inhibitor or an ARB. Our information is that Novartis is no longer promoting Tekturna.
Please contact us if you have suffered kidney failure. We have tremendous knowledge concerning kidney problems, kidney failure, kidney complications.
On April 20th, 2012, the Food and Drug Administration (“FDA”) published a press release entitled, “Safety Alerts” which included additional warnings for the blood pressure medication known as Tekturna which contains Aliskiren – the active ingredient. Tekturna is an FDA approved drug taken orally and prescribed to treat high blood pressure (hypertension). It is manufactured by Novartis. Side effects of this product include:
- Kidney Failure
If you or a loved one has taken Tekturna and suffered kidney failure, kidney injury, cardiac injury or stroke please contact one of our qualified intake specialists at 1-800-718-4658. We are currently investigating these side effect cases in all 50 states.
Tekturna was approved for use in the United States and Great Britain in 2007 for high blood pressure. It is part of a new class of drugs called Renin Inhibitors. Renin is an enzyme created by the kidneys which regulates blood pressure. Unfortunately, Renin also raises blood pressureand Tekturna is supposed to stop that event.
Tekturna should not be prescribed to patients who are diabetic and who are taking enzyme ACE inhibitors or receptor blockers.
The new warnings include risks that patients should not use Tekturna if they have diabetes or any type of kidney impairment.
The label change was announced on April 20th, 2012 concerning serious risks used by diabetics for patients with kidney failure who are also taking ACE inhibitors or angiotensin receptor blockers (ARBs). The drug company Novartis also stated in its announcement that it will remove Valturna from the marketplace, which is a single pill combination of aliskiren and valsartan by July 20, 2012.
If you would like a confidential free case review please complete the free case review on the right.
VALTURNA SIDE EFFECTS LAWYER
The experienced national defective products law firm Nadrich & Cohen LLP is investigating Valturna side effect cases throughout the country.
This high blood pressure medication also prescribed for hypertension has been taken off the market due to a clinical study which found that its use can cause a greater risk of stroke, low blood pressure, kidney damage or hyperkalemia. Valturna’s manufacturer, Novartis, as a result, stopped all marketing of Valturna and suggested to those using Valturna to have their medication changed.
We are investigating and accepting Valturna side effect cases throughout the country – in all 50 states.
The purpose of Valturna is to lower blood pressure or hypertension. It was developed by Novartis and approved by the FDA in 2009. Valturna is a combination drug which includes Aliskiren, a direct renin inhibitor (DRI) and Valsartin, an angiotensin receptor blocker – (ARB). The two are necessary for the blood vessels to come together or constrict.
Novartis apparently prematurely ended a the clinical trial in December 2011. The reason was that an unacceptably high rate of side effect patients were developing strokes, hyperkalemia, low blood pressure and kidney damage. Novartis, as a result, sent letters to medical prescribers advising them not to prescribe Valturna any longer.
The original goal for Valturna was to aid in the treatment of diabetes and hypertension. Sadly, the opposite turned out to be true. These patients were already at a higher risk for cardiovascular and renal complications due to their original illness.
Novartis ceased marketing Valturna in April 2012. As of July 20th, 2012 Valturna was no longer available on the marketplace.
Current Status: Valturna has not yet been recalled, but it is not being sold.
If you or your loved one used Valturna and suffered a stroke, please contact our office. We have offices throughout California and are handling Valturna side effect cases nationwide.
If you suffered kidney problems from Valturna please immediately contact our office. Kidney problems can lead to a life threatening condition called hyperkalemia.
Side effects from Valturna include:
- Kidney disease;
- Unacceptable high levels of potassium remaining in the blood;
- Fluid retention in the upper and lower extremities;
- Muscle damage leading to kidney failure;
- Blurry vision;
- Low blood pressure;
The most serious side effects are kidney failure, strokes and heart attacks.
Nadrich & Cohen is offering confidential, free legal consultations to victims of Valturna. If you or a loved one suffered a stroke, heart attack, kidney problem or another side effect while taking Valturna, please contact our offices at 1-800-718-4658 or by completing the inquiry on the right “Do I have a legal claim?”
We are contingency lawyers, so there is no cost for our services unless we obtain a recovery from the manufacturer.